Advertisement
To participate in the conference call, please dial (800) 510-0146 in theU.S. (617) 614-3449 for international callers) at least 15 minutes before thestart of the call. When prompted for a pass code, please enter 81583398.
Advertisement
An audio webcast of the call will be accessible at www.vionpharm.com.Those who wish to listen to the conference call on the Web should visit theInvestor Relations section of the Company's website at least 15 minutes priorto the event broadcast, and follow the instructions provided to assure thatthe necessary audio applications are downloaded and installed. These programscan be obtained at no charge to the user.
A replay of the call will be available two hours after the completion ofthe call at (888) 286-8010 in the U.S., (617) 801-6888 for internationalcallers), pass code 95705866. The replay will be available through Tuesday,April 1, 2008.
Vion Pharmaceuticals, Inc. is committed to extending the lives andimproving the quality of life of cancer patients worldwide by developing andcommercializing innovative cancer therapeutics. Vion has two agents inclinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, isbeing evaluated in a pivotal Phase II trial as a single agent in elderlypatients with de novo poor-risk acute myelogenous leukemia. Clinical trialsof Cloretazine(R) (VNP40101M) as a single agent in small cell lung cancer,with temozolomide in brain tumors, and with stem cell transplantation inadvanced hematologic malignancies, are also being conducted. Triapine(R), apotent inhibitor of a key step in DNA synthesis, is being evaluated inclinical trials sponsored by the National Cancer Institute. For additionalinformation on Vion and its product development programs, visit the Company'sInternet web site at www.vionpharm.com.
This news release contains forward-looking statements. Such statements aresubject to certain risk factors which may cause Vion's plans to differ orresults to vary from those expected, including Vion's potential inability toobtain regulatory approval for its products, delayed or unfavorable results ofdrug trials, the possibility that favorable results of earlier preclinicalstudies or clinical trials are not predictive of safety and efficacy resultsin later clinical trials, the need for additional research and testing, thepotential inability to secure external sources of funding to continueoperations, the inability to access capital and funding on favorable terms,continued operating losses and the inability to continue operations as aresult, and a variety of other risks set forth from time to time in Vion'sfilings with the Securities and Exchange Commission, including but not limitedto the risks attendant to the forward-looking statements included under Item1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2006and the Company's Form 10-Q for the quarter ended September 30, 2007. Inparticular, there can be no assurance as to the results of any of theCompany's clinical trials, that any of these trials will continue to fullaccrual, or that any of these trials will not be discontinued, modified,delayed or ceased altogether. Except in special circumstances in which a dutyto update arises under law when prior disclosure becomes materially misleadingin light of subsequent events, Vion does not intend to update any of theseforward-looking statements to reflect events or circumstances after the datehereof or to reflect the occurrence of unanticipated events.COMPANY CONTACT: Vion Pharmaceuticals, Inc. Alan Kessman, Chief Executive Officer Howard B. Johnson, Pre
